LMAN2 encodes a transmembrane lectin that functions as an intracellular carbohydrate-binding protein in the early secretory pathway, shuttling between the endoplasmic reticulum, Golgi apparatus, and plasma membrane 1. The protein plays roles in protein processing and N-glycosylation in the endoplasmic reticulum, with expression being upregulated in Alzheimer's disease brain capillaries alongside other protein processing machinery 2. LMAN2 serves as a regulatory protein for voltage-gated potassium channels, specifically modulating Kv1.2 redox-sensitive gating by promoting slow gating modes and enhancing sensitivity to extracellular reducing agents 3. In disease contexts, LMAN2 shows significant clinical relevance as a circulating biomarker, with strong associations to albuminuria progression in chr5 kidney disease patients across multiple cohorts 4. Additionally, LMAN2 is overexpressed in HER2-positive breast cancer, where it promotes tumor progression, inflammation, and activates Akt/ERK/NF-κB signaling pathways through interaction with HEATR3 5. The protein has also been identified as a potential drug target for neurodegenerative diseases through genetic and proteomic analyses 6, suggesting broad pathophysiological significance beyond its primary role in glycoprotein processing.